Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia

Abstract

To assess the impact of BCR-ABL kinase domain mutations on dasatinib response in elderly chronic myeloid leukemia (CML) patients, we analyzed the outcome of 76 individuals aged >60 affected by imatinib-resistant chronic-phase CML. We found that 36 cases (47 %) displayed mutations before dasatinib. Compared to non-mutated patients, subjects with point mutations had a worse response to dasatinib, with significantly lower rates of complete cytogenetic response (57 vs 32 %), higher percentage of primary resistance (16/36 vs 6/40) and a trend towards a shorter median event-free survival. Our data suggest that, in elderly patients, detection of BCR-ABL mutations negatively affects response to dasatinib.

DOI: 10.1007/s00277-012-1591-2

3 Figures and Tables

Statistics

01002002011201220132014201520162017
Citations per Year

90 Citations

Semantic Scholar estimates that this publication has 90 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Tiribelli2012ImpactOB, title={Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia}, author={Mario Tiribelli and Roberto Latagliata and Luigiana Luciano and Fausto Castagnetti and Antonella Gozzini and Giovanna Rege Cambrin and Mario Annunziata and Fabio Stagno and Patrizia Pregno and Francesco Albano and Elisabetta Abruzzese and Pellegrino Musto and Enrico Montefusco and Carmen Fava and Renato Fanin and F. Pane and Gianantonio Rosti and Massimo Breccia and Giuliana Alimena and Paolo Giovanni Vigneri}, journal={Annals of Hematology}, year={2012}, volume={92}, pages={179-183} }